Taurodeoxycholic Acid (TDCA): A Comprehensive Reference
1. Identity and Chemical Characterization
Chemical Names and Classification
Taurodeoxycholic acid is a bile acid. It is also known by the abbreviation TDCA and the common synonym taurodeoxycholate. It is a bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. The systematic IUPAC name of the sodium salt form is sodium 2-[[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonate. It is also known as: 1180-95-6 (CAS number), taurodeoxycholate sodium salt, taurodeoxycholic acid sodium salt, sodium taurodeoxylate, and taurodeoxycholate (sodium salt).
This compound is a closely related isomer of taurochenodeoxycholic acid and tauroursodeoxycholic acid, sharing the exact molecular formula and molecular weight. The molecular mass of TDCA is 498.3 g/mol, similar to that of PFOS (499.0 g/mol), and it is impossible to distinguish the two compounds using nominal-resolution mass spectrometry (MS).
Structural Chemistry
Taurodeoxycholic acid (TDCA) is a bile acid derivative formed by the conjugation of deoxycholic acid with taurine. The primary bile acids are synthesized in the liver from cholesterol, then conjugated to either taurine or glycine. Specifically, in the body, deoxycholate biosynthesis begins with the enzymatic oxidation, isomerization, and reduction of cholesterol in the liver to form cholic acid. In the liver, cholic acid is then chemically linked to one of two amino acids (taurine or glycine) to form the conjugated cholic acids. First, conjugated cholic acid is dehydroxylated to form conjugated deoxycholate, which, in its taurine-conjugated form, is taurodeoxycholic acid.
Natural bile salts consist of a family of amphipathic steroids produced by cholesterol metabolism in the liver. Bile salts are classified as primary (synthesized in the liver) or secondary (produced by bacterial transformation of bile salts within the gut). TDCA belongs to the secondary class. TDCA is a secondary bile acid that requires microbiota for its generation. Its level is much lower in germ-free mice compared to conventionally raised mice, while the levels of its precursors, taurochenodeoxycholic acid (TCDCA) and taurocholic acid (TCA), are higher in germ-free animals.
Natural Sources and Forms
Taurodeoxycholic acid (TDCA) is a taurine-conjugated bile acid naturally present in the bile of mammals. It is a normal constituent of human bile and intestinal fluid. Upon secretion into the gut, primary bile acids are metabolized by the gut microbiota to produce secondary bile acids, including deoxycholic acid (DCA), lithocholic acid (LCA), and their conjugates by combining with glycine or taurine, of which TDCA is one such conjugated secondary bile acid. The human bile acid pool mainly consists of primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA), and secondary bile acids DCA, LCA, TDCA, and a small amount of UDCA and TUDCA.
Sodium taurodeoxycholate and ursodeoxycholic acid are major constituents of black bear bile, which has been used in traditional Chinese medicine for thousands of years. Sodium taurodeoxycholate is a bile salt-related, anionic detergent used for isolation of membrane proteins including inner mitochondrial membrane proteins.
Taurodeoxycholic acid is a primary bile acid that aids in the digestion of sterols and fats due to its biocompatibility and potential for functionalization. Any neutral detergent, and also mild anionic detergents like taurodeoxycholic acid, can be used for solubilization of biological membranes.
Common Preparations
Taurodeoxycholic acid sodium salt (taurodeoxycholate sodium salt) is classified among gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretics). It is used as a cholagogue and choleretic, and also industrially as a fat emulsifier. In research settings, TDCA is available as a reagent-grade sodium salt powder used for biochemical and cell biology applications. The advantage of bile acids in therapeutic use is that they might be administered via oral, subcutaneous, and intravenous routes of application.
2. Traditional and Historical Use
For centuries, traditional Chinese medicine has valued animal bile for its use in pharmacological and clinical applications. Sodium taurodeoxycholate and ursodeoxycholic acid are major constituents of black bear bile, which has been used in traditional Chinese medicine for thousands of years. Bear bile was historically employed to treat a number of diseases including jaundice, summer diarrhea, abdominal pain due to hepatobiliary diseases and gastric malfunction, biliary ascariasis, infectious skin diseases, the common cold, intestinal worms, and inflammation of the throat.
UDCA and TUDCA are the major components of black bear bile, which has been used in traditional Chinese medicine for the treatment of numerous diseases for centuries. From the perspective of traditional Chinese medicine (TCM), bear bile shows a remarkable capacity for treating 'liver heat' and reducing 'liver fire', which are TCM terms referring to the pathological phenomena concerning the liver. While TDCA co-occurs with these better-characterized bile acids in bear bile, traditional TCM applications were directed at the whole bile extract rather than isolated TDCA specifically.
Historically, bile acids like TDCA have played a significant role in traditional medicine, especially in Eastern practices. In Traditional Chinese Medicine (TCM), bile extracts from animals were employed alongside botanicals. Due to ethical concerns over bear farming and extraction methods, such as the invasive "free-dripping fistula technique" established in China in the 1980s, commercial production has shifted away from natural bear bile sources. Along with the rising concerns over endangered species, over the decades scientists have developed new ways of producing this bile acid through the chemical transformation of cholic acid and chenodeoxycholic acid from bovine bile.
It is important to note that documented traditional use refers to bile extracts containing multiple bile acids collectively. There is no historical tradition of using isolated TDCA as a stand-alone preparation. The compound's identity as a discrete chemical entity is a product of modern analytical biochemistry rather than traditional pharmacopoeia.
3. Key Constituents and Active Compounds
Chemical Composition
TDCA is itself a single chemical entity—the taurine amide conjugate of deoxycholic acid. As such, discussion of "key constituents" pertains to its structural relationship with related bile acids and its behavior within the broader bile acid pool. Bile acids are synthesized from cholesterol in the liver and further metabolized by the gut microbiota into secondary bile acids. Bile acid synthesis is under negative feedback control through activation of the nuclear receptor farnesoid X receptor (FXR) in the ileum and liver.
Biosynthesis and Microbial Production
Primary bile acids are biotransformed by the gut microbiota. These reactions include deconjugation catalyzed by bile salt hydrolases (BSH), epimerization to change the orientation of the hydroxyl groups on the steroid nucleus of the bile acids, and 7-dehydroxylation. The 7-dehydroxylation of taurocholic acid by intestinal bacteria (principally certain Clostridium spp.) yields TDCA. Longitudinal analysis of gut microbiota in cancer cachexia models identified an ASV (amplicon sequence variant) identified as Xylanibacter rodentium, as a bacterium potentially involved in the reduced production of TDCA. Stable isotope-based experiments highlighted a robust decrease in the microbial 7α-dehydroxylation (7α-DH) activity in cachectic mice.
4. Mechanisms of Action
Lipid Digestion and Detergent Activity
Bile acids are physiological detergents that absorb, distribute, metabolize, and excrete nutrients, drugs, and xenobiotics. Bile acids also are signal molecules and metabolic integrators that activate nuclear farnesoid X receptor (FXR) and membrane Takeda G protein-coupled receptor 5 (TGR5) to regulate glucose, lipid, and energy metabolism. TDCA participates in this detergent function as a component of the intestinal bile acid pool, contributing to lipid emulsification and the activation of pancreatic lipases.
Receptor Signaling: FXR and TGR5
TGR5 is crucial for biliary homeostasis by working together with other bile acid receptors. TGR5 and farnesoid X receptor (FXR) are the two most characterized receptors that have a relatively high affinity to bile acids. Unlike FXR, a nuclear protein that is activated by primary bile acids, TGR5 is activated by all known bile acids regardless of their conjugation status. TGR5 has a high binding affinity to secondary bile acids, that is, lithocholic acid (LCA) and deoxycholic acid (DCA), as well as their taurine and glycine derivatives. As the taurine conjugate of DCA, TDCA is therefore a TGR5 agonist.
The effects of bile acids on energy metabolism may be mainly due to activation of TGR5 by secondary bile acids (T/LCA and T/DCA). TGR5 activation downstream of TDCA binding can trigger a cAMP-mediated cascade; FXR and TGR5 are coexpressed in enteroendocrine L cells; FXR induces TGR5 to activate cAMP and intracellular Ca²⁺ to secrete glucagon-like peptide-1 (GLP-1), which stimulates insulin secretion from pancreatic β cells.
Immune Regulation via P2Y10 Receptor
A mechanistically important and recently characterized action of TDCA is its role in intestinal immune homeostasis. Microbiota metabolite taurodeoxycholic acid (TDCA) binds to the P2Y10 receptor on innate lymphoid cells (ILCs) to initiate downstream Ca²⁺ and RhoA signaling pathways. TDCA-P2Y10 engagement induces Zfp414 transcription to prime expression of CD69 and integrin αE on ILCs, leading to intestinal residency of ILCs.
Decreased levels of TDCA or P2Y10 deficiency abrogates the intestinal residency of ILCs, resulting in more severe intestinal inflammation. TDCA administration can enhance intestinal tissue residency of ILCs and promote protection against intestinal inflammation.
Oncogenic Signaling via YAP and VDR
The secondary bile acid taurodeoxycholic acid (TDCA) can activate YAP (Yes-associated protein) via the vitamin D receptor (VDR) to promote melanoma metastasis. This is a context-dependent mechanism noted in preclinical studies; the Hippo/YAP pathway plays an important role in the development of cancers, and previous studies have reported that bile acids can activate YAP to promote tumorigenesis and tumor progression.
Cholesterol Metabolism and Hepatic Homeostasis
Bile acid synthesis is the most significant pathway for catabolism of cholesterol and for maintenance of whole body cholesterol homeostasis. In the context of cancer cachexia, in vitro, TDCA prevented myotube atrophy, whereas in vivo hepatic whole transcriptome analysis revealed that TDCA administration to cachectic mice improved the unfolded protein response and cholesterol homeostasis pathways.
Detergent-Related Cytotoxicity
Like other secondary bile acids, TDCA possesses concentration-dependent cytotoxicity due to its amphipathic, membrane-disrupting properties. Bile acid cytotoxicity correlates with the relative hydrophobicity of the bile acid. The bile acid concentration at which 50% growth inhibition occurred was similar for all cell lines and increased in the following order: deoxycholic acid = chenodeoxycholic acid < taurodeoxycholic acid < ursodeoxycholic acid < taurochenodeoxycholic acid < cholic acid < tauroursodeoxycholic acid. This indicates that TDCA is more cytotoxic than unconjugated or more hydrophilic bile acids at the same concentration, but less cytotoxic than deoxycholic acid itself in in vitro models.
Erythrocytes incubated with increasing concentrations of the hydrophobic bile salt TDC (from 0.5 to 10 mM) showed progressively increased hemolysis. At increasing TDC concentrations, hemolysis was progressively increased. At increasing TDC concentrations (from 0.25 to 2.5 mM), cytotoxicity in CaCo2 cells was progressively increased.
5. Scientific Evidence by Area of Use
5.1 Colorectal Cancer Risk Biomarker
Serum concentration of taurodeoxycholic acid, a downstream microbial metabolite of cholic acid, is associated with a strong increased risk of colorectal cancer among women. This association has been investigated in prospective epidemiological studies.
Taurodeoxycholic acid (TDCA) concentrations were positively correlated with risk of colon cancer. Metabolomic analysis showed increased bile acid metabolite TDCA in the colon of smoke-exposed mice and in the colon of individuals consuming high-fat diets, which were associated with an increased risk of colorectal cancers.
Colorectal cancer (CRC) is one of the most frequent causes of cancer death worldwide and is associated with adoption of a diet high in animal protein and saturated fat. Saturated fat induces increased bile secretion into the intestine. Increased bile secretion selects for populations of gut microbes capable of altering the bile acid pool, generating tumor-promoting secondary bile acids such as deoxycholic acid and lithocholic acid. Vegetarian diets favor glycine conjugation while diets high in animal protein favor taurine conjugation. Metabolism of taurine conjugated bile acids by gut microbes generates hydrogen sulfide, a genotoxic compound.
The secondary bile acid taurodeoxycholic acid (TDCA) can activate YAP via the vitamin D receptor (VDR) to promote melanoma metastasis—a finding from preclinical cell biology research. Secondary bile acids (SBAs), which are metabolites produced by gut microbiota, have been implicated in both carcinogenic and anticancer processes. Their molecular mechanisms and biological effects are under active study. The carcinogenic activities of SBAs include DNA damage, promotion of oxidative stress, and modulation of signaling pathways that drive tumorigenesis.
Evidence strength: The colorectal cancer association for TDCA is currently epidemiological and pre-clinical (animal models and cell studies). No randomized clinical trials using TDCA as an intervention for cancer prevention have been reported. The biomarker associations are largely observational and do not establish causality.
5.2 Lung Cancer Screening Biomarker
The determination of taurodeoxycholic acid 3-sulfate in blood samples may potentially be useful as a risk factor and screening biomarker for lung cancer prevention. This observation comes from metabolomic analyses; no clinical validation studies specific to TDCA sulfate as a diagnostic tool have yet been published in peer-reviewed, interventional trial form.
Evidence strength: Preliminary; metabolomic and observational data only. Human clinical validation is lacking.
5.3 Intestinal Immunity and Inflammatory Bowel Disease
Innate lymphoid cells (ILCs) play critical roles in innate immunity, epithelial barrier protection, and tissue homeostasis. However, the maintenance machinery of intestinal tissue residency of ILCs was previously elusive. A 2025 study published in Science Advances showed that gut microbiota is necessary for the maintenance of intestinal tissue residency of ILCs.
TDCA is a ligand to P2Y10 receptor that is highly expressed on intestinal ILCs. TDCA-P2Y10 engagement initiates downstream Ca²⁺ and RhoA signaling pathways to promote Zfp414 transcription, leading to elevated expression of CD69 and integrin αE on ILCs. TDCA administration can enhance intestinal tissue residency of ILCs and promote protection against intestinal inflammation.
Thus, TDCA might be used as a potential drug to treat patients with inflammatory bowel disease. The authors used germ-free mouse models and adoptive cell transfer experiments to demonstrate this mechanism.
Using germ-free and antibiotic-treated mice, the authors revealed that normal microbiota are required for maintenance of ILC tissue residency and that microbiota disruption leads to ILC egress.
Evidence strength: Preclinical only (mouse models, in vitro cell experiments). The P2Y10-TDCA axis is mechanistically compelling, but no human clinical trials have tested TDCA for inflammatory bowel disease as of the available literature.
5.4 Cancer Cachexia and Hepatic Cholesterol Homeostasis
Alterations in bile acid profile and pathways contribute to hepatic inflammation in cancer cachexia, a syndrome worsening the prognosis of cancer patients. As the gut microbiota impinges on host metabolism through bile acids, a 2025 study aimed to explore the functional contribution of gut microbial dysbiosis to bile acid dysmetabolism and associated disorders in cancer cachexia.
Using three mouse models of cancer cachexia (the C26, MC38 and HCT116 models), the researchers evidenced a reduction in the hepatic levels of several secondary bile acids, mainly taurodeoxycholic (TDCA). This reduction in hepatic TDCA occurred before the appearance of cachexia.
TDCA administration reversed hepatic cholesterol accumulation in these mice. Altogether, this work highlights the contribution of the gut microbiota to bile acid dysmetabolism and the therapeutic interest of the secondary bile acid TDCA for hepatic cholesterol homeostasis in the context of cancer cachexia.
A review in Signal Transduction and Targeted Therapy (2026) noted that a recent study highlighted the contribution of gut microbial dysbiosis to perturbing bile acid dysmetabolism in individuals with cancer cachexia, especially the reduction in the levels of several secondary bile acids, mainly taurodeoxycholic bile acids, which occur before the development of cachexia. These findings underscore the therapeutic potential of taurodeoxycholic acid for hepatic cholesterol homeostasis in cachexia.
Evidence strength: Preclinical (three mouse tumor models). The finding that TDCA reduction precedes cachexia is mechanistically significant, and TDCA supplementation reversed certain hepatic metabolic defects in these models. No human trials have been conducted.
5.5 Colonic Epithelial Cytotoxicity (In Vitro)
Bile acids have been implicated as tumor promoters that enhance epithelial proliferation and the development of colonic tumors. One study investigated the effects of bile acids on the growth of in vitro models of human colonic epithelial cells. Cell lines with varying degrees of differentiation (Caco2, HT29, LS174T, and LoVo) were studied. Cell viability and number were measured by a tetrazolium (MTT) spectrophotometric assay.
Enhanced cell growth was not observed with any bile acid over the range 10 nmol/L to 2.5 mmol/L. Cytotoxicity was consistently observed at concentrations of unconjugated bile acids greater than 0.1 mmol/L. Co-incubation of tauroursodeoxycholic acid (TUDC) with taurodeoxycholic acid (TDC) reversed the short-term (30-minute) cytotoxicity and release of glycoprotein induced by TDC regardless of differentiation status.
Evidence strength: In vitro cell culture data. Results cannot be directly extrapolated to human physiology or therapeutic dosing.
5.6 Lipid Digestion and Fat Emulsification
Primary bile acids are responsible for emulsifying dietary fats and activating pancreatic lipases in the small intestine. TDCA, as a secondary bile acid present in the gastrointestinal lumen, contributes to this emulsification pool. Conjugated deoxycholate is deconjugated to form free deoxycholate, which participates, along with the other bile acids, in the solubilization of dietary lipids. In its taurine-conjugated form, TDCA is more resistant to precipitation under the acidic conditions of the biliary system than its unconjugated precursor, and thus participates in fat solubilization through much of the upper gastrointestinal tract.
Evidence strength: This is an established physiological role based on bile acid biochemistry; no clinical trials specifically targeting TDCA for enhanced lipid absorption exist.
6. Body Systems and Health Areas Associated with TDCA
- Gastrointestinal system: Lipid emulsification, fat-soluble vitamin absorption, modulation of colonic epithelial cell biology, and colon cancer risk association.
- Hepatobiliary system: Component of the enterohepatic circulation; altered TDCA levels are linked to hepatic cholesterol dysregulation in cancer cachexia; altered bile acid patterns provide a rich source of biomarkers for early detection of specific liver injuries.
- Intestinal immune system: Innate lymphoid cells (ILCs) play critical roles in innate immunity, epithelial barrier protection, and tissue homeostasis, and TDCA is now identified as a key regulator of ILC intestinal residency via the P2Y10 receptor.
- Gut microbiome: TDCA levels serve as a readout of microbial 7α-dehydroxylation activity and reflect gut microbiota compositional health. Emerging evidence suggests that microbiota-derived secondary bile acids play a critical role in regulation of intestinal immunity.
- Oncology: Elevated serum TDCA is associated with colorectal cancer risk; its sulfated derivative has been proposed as a lung cancer biomarker; and TDCA may activate pro-tumorigenic YAP signaling via VDR in melanoma contexts.
- Metabolic/energy homeostasis: As a TGR5 agonist, TDCA participates in the bile acid–metabolic signaling axis that connects gastrointestinal bile acid sensing to systemic energy and glucose metabolism. The gut-to-liver axis plays a critical role in the transformation of primary bile acids to secondary bile acids, in the regulation of bile acid synthesis to maintain composition within the bile acid pool, and in the regulation of metabolic homeostasis to prevent hyperglycemia, dyslipidemia, obesity, and diabetes.
7. Dosage Forms and Reported Dosages
TDCA is not approved by any regulatory agency as a pharmaceutical drug for human use, and it is not established as a dietary supplement with standardized dosing guidelines. The use of taurodeoxycholic acid in nutritional products is relatively recent compared to traditional bile acids.
In research settings, the following concentrations and doses have been reported in published studies:
- In vitro cytotoxicity studies: Enhanced cell growth was not observed with any bile acid over the range 10 nmol/L to 2.5 mmol/L. Erythrocytes were incubated with TDC at concentrations from 0.5 to 10 mM to produce hemolysis dose-response curves. At TDC concentrations from 0.25 to 2.5 mM, cytotoxicity in CaCo2 cells was progressively increased.
- In vivo mouse models (cancer cachexia): TDCA prevented myotube atrophy in vitro, and in vivo hepatic whole transcriptome analysis revealed that TDCA administration to cachectic mice improved the unfolded protein response and cholesterol homeostasis pathways. Specific dose amounts in mg/kg are not fully described in the available abstract-level information.
- Analytical/detection context: Fish tissue was spiked with 1.16 μg/g taurodeoxycholic acid (TDCA) as an interfering compound in PFOS analytical validation studies—not a therapeutic context.
No human clinical pharmacokinetic or dose-escalation studies with isolated TDCA have been identified in the published peer-reviewed literature. For comparison, related taurine-conjugated bile acids used therapeutically (such as TUDCA) have been studied in humans at doses ranging from 250 to 1750 mg/day in various clinical trials, but these data cannot be directly applied to TDCA, which has distinct pharmacology and a different safety profile.
8. Safety Considerations and Interactions
Cytotoxicity as a Hydrophobic Bile Acid
Bile acid cytotoxicity correlates with the relative hydrophobicity of the bile acid. TDCA is more hydrophobic than hydrophilic bile acids (such as UDCA and TUDCA), placing it in an intermediate-to-high risk range for concentration-dependent membrane disruption. At increasing TDC concentrations, hemolysis is progressively increased. For each TDC concentration, TDC-induced hemolysis is significantly enhanced in the presence of indomethacin (a non-steroidal anti-inflammatory drug), demonstrating a pharmacodynamic interaction between TDCA and NSAIDs at the membrane level in experimental models.
Association with Colorectal Cancer Risk
Serum concentration of taurodeoxycholic acid, a downstream microbial metabolite of cholic acid, is associated with a strong increased risk of colorectal cancer among women. This represents an endogenous safety signal relevant to elevated physiological levels rather than to any supplement product, but it underscores that chronically high TDCA concentrations—such as those arising from a high-fat, high-animal-protein diet—are associated with adverse oncological outcomes.
Interaction with Mass Spectrometry Diagnostics
Taurodeoxycholic acid and its isomers have molecular masses similar to perfluorooctanesulfonic acid (PFOS) and therefore may interfere with interpretation of mass spectrometry data, leading to a false indication of the presence of PFOS in a biological sample. Taurodeoxycholic acid (TDCA) is a well-known interferent in the detection of PFOS in biological samples, as its mass is similar to that of PFOS, and conventional MS cannot distinguish the two in biological samples. This is a clinical/analytical safety consideration for laboratories using low-resolution MS to test for environmental contaminants in biological matrices containing high bile acid levels.
Oncogenic Potential in Preclinical Models
Previous studies have reported that the primary bile acids, and some secondary bile acids such as DCA and LCA, are promoters of tumorigenesis of various cancers including hepatocellular carcinoma and colorectal cancer. The secondary bile acid taurodeoxycholic acid (TDCA) can activate YAP via the vitamin D receptor (VDR) to promote melanoma metastasis in preclinical models. These findings suggest a potential oncogenic risk associated with sustained supraphysiological TDCA exposure, though human evidence is not available.
Diet-Microbiome-TDCA Axis and Cancer Risk
Saturated fat induces increased bile secretion into the intestine. Increased bile secretion selects for populations of gut microbes capable of altering the bile acid pool, generating tumor-promoting secondary bile acids such as deoxycholic acid and lithocholic acid. Vegetarian diets favor glycine conjugation while diets high in animal protein favor taurine conjugation. Metabolism of taurine conjugated bile acids by gut microbes generates hydrogen sulfide, a genotoxic compound. This genotoxic byproduct pathway is mechanistically relevant to the colorectal cancer risk signal observed with elevated TDCA.
Potential Protective Interaction with TUDCA
Co-incubation of tauroursodeoxycholic acid (TUDC) with taurodeoxycholic acid (TDC) reversed the short-term cytotoxicity and release of glycoprotein induced by TDC regardless of differentiation status. Because tauroursodeoxycholic acid alters the cytotoxicity of hydrophobic bile acids in vitro, further understanding of bile acid interactions in the colon may have important implications in altering tumor promotion. This suggests that TUDCA and TDCA exhibit a pharmacological interaction relevant to colonic mucosal safety.
NSAID Interaction
For each TDC concentration, TDC-induced hemolysis is significantly enhanced in the presence of indomethacin in experimental models. This interaction has been characterized in vitro and points to a potential additive membrane-disrupting effect when TDCA and certain NSAIDs are present simultaneously at high concentrations, though clinical relevance in humans at physiological bile acid concentrations has not been established.
9. Relationship to Related Bile Acids
TDCA must be clearly distinguished from its structural isomers and precursors, which are better characterized pharmacologically:
- Deoxycholic acid (DCA): The unconjugated precursor of TDCA, produced by bacterial 7α-dehydroxylation of cholic acid. More cytotoxic than TDCA due to greater hydrophobicity.
- Tauroursodeoxycholic acid (TUDCA): A closely related isomer sharing the exact molecular formula and molecular weight as TDCA, but with markedly different (and generally cytoprotective rather than cytotoxic) biological properties. TUDCA is the taurine conjugate of ursodeoxycholic acid rather than deoxycholic acid.
- Taurochenodeoxycholic acid (TCDCA): Another isomeric taurine-conjugated secondary bile acid that shares the molecular formula of TDCA, important in the same enterohepatic bile acid pool.
Recent studies have highlighted the involvement of tauro- and glyco-conjugated bile acids in the pathogenesis of metabolic syndrome, dementia, and cancer cachexia. This broader context situates TDCA within a rapidly evolving field linking gut microbiota-derived bile acid metabolites to systemic metabolic and immunological health.
10. Status as a Dietary Supplement and Research Outlook
The use of taurodeoxycholic acid in nutritional products is relatively recent compared to traditional bile acids. Preclinical studies have demonstrated that taurodeoxycholic acid may exert cytoprotective effects, particularly in the context of liver health. TDCA and similar bile salts have been shown to reduce endoplasmic reticulum (ER) stress in cellular and animal models, suggesting potential for supporting hepatic function.
As of the available literature, TDCA has not received approval from the FDA, EMA, or any major regulatory authority as a pharmaceutical drug or as a specifically characterized dietary supplement ingredient. It does not appear in the USP, European Pharmacopoeia, WHO monographs, or ESCOP monographs as a standalone therapeutic agent. Its research status is that of an endogenous biomarker and a preclinical mechanistic probe, with emerging evidence of both beneficial (intestinal immune maintenance, anti-cachexia) and harmful (pro-oncogenic at elevated levels) physiological roles.
The key areas of active investigation as of 2025–2026 are:
- TDCA as a therapeutic agent for inflammatory bowel disease, based on P2Y10/ILC intestinal residency mechanisms.
- TDCA as a metabolic modulator in cancer cachexia and hepatic cholesterol dysregulation.
- TDCA serum levels as an epidemiological biomarker for colorectal and lung cancer risk stratification.
- TDCA's dual role as both a potential carcinogen (via YAP/VDR signaling at elevated levels) and a physiologically essential secondary bile acid at normal concentrations.
References
Go back